- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04386993
De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer (DeCRESCEndo)
October 23, 2023 updated by: Washington University School of Medicine
De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer (DeCRESCEndo)
The goal of this study is to evaluate short course radiation in the post-operative female pelvis after hysterectomy in stage III-IVA endometrial adenocarcinoma patients, or any stage patients with uterine serous or carcinosarcoma histology.
The investigators hypothesize that short course pelvic radiation will have an acute and late grade 3-4 toxicity rate < 10%, and patients will benefit from both convenient and effective loco-regional control comparable to the traditional 5-6 weeks of radiation.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
25
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jessika Contreras, M.D.
- Phone Number: 314-747-7236
- Email: jcontreras@wustl.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Sub-Investigator:
- Andrea Hagemann, M.D.
-
Sub-Investigator:
- Julie Schwarz, M.D., Ph.D.
-
Sub-Investigator:
- Yi Huang, M.S.
-
Contact:
- Jessika Contreras, M.D.
- Phone Number: 314-747-7236
- Email: jcontreras@wustl.edu
-
Principal Investigator:
- Jessika Contreras, M.D.
-
Sub-Investigator:
- Stephanie Markovina, M.D., Ph.D.
-
Sub-Investigator:
- Matthew Powell, M.D.
-
Sub-Investigator:
- Lindsay Kuroki, M.D.
-
Sub-Investigator:
- L. Stewart Massad, M.D.
-
Sub-Investigator:
- Carolyn McCourt, M.D.
-
Sub-Investigator:
- David Mutch, M.D.
-
Sub-Investigator:
- Premal Thaker, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically or cytologically confirmed stage IIIA-IVA endometrial cancer, or any stage I-IVA where any proportion of the tumor is uterine serous, clear cell, de-differentiated, or carcinosarcoma histology.
- Must have already undergone radical hysterectomy. Hysterectomy may have occurred no more than one year prior to enrollment.
- At least 18 years of age.
- ECOG performance status ≤ 2
Minimal bone marrow and organ function as defined below:
- Leukocytes ≥ 1,000 cumm
- Absolute neutrophil count ≥ 500 cumm
- Platelets ≥ 50,000 cumm
- Hemoglobin ≥ 7g/dL
- Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Exclusion Criteria:
- Prior radiation to the pelvis.
- Currently receiving any investigational agents.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, inflammatory bowel disease, or irritable bowel disease.
- Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to registration. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMRT
-Five 5-Gy fractions of IMRT will be given to the pelvis with elective simultaneous boost to any suspicious lymph node or residual disease to 30 Gy. -*Brachytherapy boost (at the discretion of the PI) within 2 weeks of radiation therapy completion. Once or twice weekly for three weeks |
Radiation should be delivered over the course of 1-2 weeks (allowing for weekends/holidays).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of acute hematologic, gastrointestinal, and genitourinary adverse events
Time Frame: From start of radiation through Day 90
|
From start of radiation through Day 90
|
Incidence of late hematologic, gastrointestinal, and genitourinary adverse events
Time Frame: From Day 91 through month 12
|
From Day 91 through month 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in patient-reported urinary and gastrointestinal toxicity as measured by PRO-CTCAE
Time Frame: Baseline, 2 weeks, and 3 months post-completion of radiation
|
|
Baseline, 2 weeks, and 3 months post-completion of radiation
|
Change in patient-reported urinary and gastrointestinal toxicity as measured by bowel/bladder domains of EPIC-26
Time Frame: Baseline, 2 weeks, 3 months, 6 months, and 12 months post-completion of radiation
|
|
Baseline, 2 weeks, 3 months, 6 months, and 12 months post-completion of radiation
|
Change in quality of life as measured by FACT-En
Time Frame: Baseline, 2 weeks, 3 months, 6 months, and 12 months post-completion of radiation
|
|
Baseline, 2 weeks, 3 months, 6 months, and 12 months post-completion of radiation
|
Locoregional control
Time Frame: Up to 12 months post-completion of radiation
|
-Locoregional recurrence is defined as histologic or radiographic evidence of cancer in the previously resected site or regional lymph nodes included in the radiated field.
|
Up to 12 months post-completion of radiation
|
Distant control
Time Frame: Up to 12 months post-completion of radiation
|
-Distant recurrence is defined as histologic or radiographic evidence of cancer outside of the radiated field.
|
Up to 12 months post-completion of radiation
|
Overall survival
Time Frame: Up to 12 months post-completion of radiation
|
-Number of participants alive at the time of completion of follow-up
|
Up to 12 months post-completion of radiation
|
Disease-free survival
Time Frame: Up to 12 months post-completion of radiation
|
-Disease-free survival is defined as survival with no evidence of disease recurrence or death
|
Up to 12 months post-completion of radiation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jessika Contreras, M.D., Washington University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 7, 2020
Primary Completion (Estimated)
August 31, 2025
Study Completion (Estimated)
August 31, 2025
Study Registration Dates
First Submitted
May 8, 2020
First Submitted That Met QC Criteria
May 8, 2020
First Posted (Actual)
May 13, 2020
Study Record Updates
Last Update Posted (Actual)
October 26, 2023
Last Update Submitted That Met QC Criteria
October 23, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202004237
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Individual participant data that underlie the results reported in the article, after deidentification (text, tables, figures, and appendices) for individual participant data meta-analysis by investigators whose proposed use of data has been approved by an independent review committee ("learned intermediary") identified for this purpose.
IPD Sharing Time Frame
Proposals may be submitted up to 36 months following article publication.
IPD Sharing Access Criteria
Please contact Dr. Alexander Lin at alexanderlin@wustl.edu
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Batman Training and Research HospitalEskisehir Osmangazi UniversityCompletedGynecologic Cancer | Endometrial Cancer Stage
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingAdvanced Endometrial CancerChina
-
Novartis PharmaceuticalsCompletedAdvanced Endometrial CancerBelgium, France, Italy, Canada, Spain, Australia, Germany, United States, Japan, Brazil, Singapore, Russian Federation, Poland
-
Samsung Medical CenterRecruitingEndometrial Cancer Stage IKorea, Republic of
-
Duke UniversityDuke Cancer InstituteCompleted
-
Far Eastern Memorial HospitalCompletedOutcome of Endometrial CancerTaiwan
-
Rambam Health Care CampusCompletedSerous Papillary Endometrial CancerIsrael
-
Masonic Cancer Center, University of MinnesotaCompletedCervical Cancer | Ovarian Cancer | Uterine Endometrial CancerUnited States
Clinical Trials on Intensity modulated radiation therapy
-
National Cancer Institute (NCI)TerminatedLocally Recurrent Head and Neck Squamous Cell Carcinoma | Nasopharyngeal Squamous Cell Carcinoma | Sinonasal Squamous Cell CarcinomaUnited States
-
Mount Sinai Hospital, CanadaPrincess Margaret Hospital, CanadaActive, not recruitingAdult Soft Tissue SarcomaCanada, United States, Belgium
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate AdenocarcinomaUnited States, Canada, Hong Kong, Switzerland, India, Ireland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck CarcinomaUnited States
-
Institut Cancerologie de l'OuestCompletedCervical Cancer | Prostate Cancer | Anal Canal CancersFrance
-
Memorial Sloan Kettering Cancer CenterCompletedMetastatic DiseaseUnited States
-
University Health Network, TorontoOntario Cancer Research NetworkCompleted
-
Xiangya Hospital of Central South UniversityRecruitingNasopharyngeal CarcinomaChina
-
Alberta Health servicesCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States